sinc
outbreak
sever
acut
respiratori
syndrom
sar
coronaviru
start
china
decemb
increas
evid
exist
comorbid
older
age
compromis
immun
system
higher
risk
develop
sever
even
fatal
respiratori
diseas
cancer
transplant
patient
also
consid
risk
group
especi
may
treat
immunesuppress
immunestimul
drug
current
review
focus
effect
immunesuppress
immunestimul
drug
host
immun
report
short
introduct
drug
follow
summari
result
identifi
studi
rel
drug
hypothesis
drug
select
like
categoris
one
two
group
may
harm
patient
put
risk
increas
morbiditymort
associ
infect
may
use
treat
immunopatholog
associ
sever
persist
viral
infect
clinic
impact
review
thu
twofold
aim
identifi
drug
clinician
think
take
patient
protect
increas
harm
also
drug
could
potenti
benefici
fight
diseas
review
cover
inform
avail
today
pandem
progress
opportun
respons
collect
prospect
data
use
establish
randomis
control
trial
involv
drug
interest
cohortbas
translat
studi
cytotox
chemotherapylowdos
steroid
nonsteroid
antiinflammatori
drug
nsaid
tumour
necrosi
factor
tnf
blockadejanu
kinas
jak
search
conduct
use
ovid
medlin
total
studi
includ
review
differ
type
immunesuppress
immunestimul
drug
group
tabl
show
search
term
number
studi
includ
review
search
yield
result
includ
supplementari
tabl
key
casereport
interest
highlight
coronaviru
one
common
viral
pathogen
identifi
paediatr
cancer
patient
undergo
chemotherapi
second
human
rhinoviru
viral
codetect
frequent
patient
cancer
acut
respiratori
infectionsa
brain
biopsi
metagenom
nextgener
sequenc
case
child
preb
acut
lymphoblast
leukaemia
case
young
woman
stage
iiia
breast
cancer
report
diagnosi
coronaviru
follow
treatment
cancer
use
highdos
chemotherapi
regimen
autolog
bone
marrow
stem
cell
transplant
electron
microscopi
reveal
coronaviru
pneumonia
coronaviru
potenti
consid
differenti
diagnos
respiratori
failur
patient
undergon
highdos
chemotherapi
autolog
bone
marrow
transplant
addit
observ
made
relat
specif
treatment
although
hiv
proteas
inhibitor
lopinavir
suggest
lowmicromolar
inhibitor
merscov
differ
mechanist
class
hiv
coronaviru
fall
meant
low
affin
coronaviru
strain
compar
hiv
follow
compound
shown
activ
vitro
sarscov
viru
enzym
inhibitor
bd
adenoviru
vector
human
monoclon
antibodi
neutralis
antibodi
specif
sarscov
recombin
type
interferon
induc
ampligen
therapeut
antibodi
equin
antisarscov
f
ab
monoclon
antibodi
attach
inhibitor
urtica
dioica
lectin
griffithsin
host
immun
system
use
cancer
chemotherapi
treatment
acut
lymphoblast
myeloblast
leukaemia
found
specif
inhibitor
sar
coronaviru
carbohydratebind
agent
cba
may
abl
block
envelop
virus
hiv
entri
process
coronavirus
influenza
virus
exampl
envelop
virus
may
highli
suscept
antivir
action
cba
genom
sarscov
encod
five
major
protein
spike
protein
envelop
protein
e
membran
glycoprotein
nucleocapsid
protein
n
e
may
help
host
cell
induc
product
protect
fight
viru
bananin
hydroxymethyl
act
zinc
chelat
therefor
interest
target
inhibit
immunodefici
viru
type
zinc
finger
rnabind
nucleocapsid
protein
bananin
convert
bananin
monophosph
bnp
togeth
vitamin
avitamin
conjug
could
inhibit
infecti
virion
encapsid
target
bnp
shown
present
also
sarsassoci
coronaviru
make
possibl
therapeut
candid
coronaviru
strain
one
common
viral
pathogen
identifi
paediatr
cancer
patient
undergo
chemotherapi
patient
preb
acut
lymphoblast
leukaemia
breast
cancer
undergon
chemotherapi
report
case
coronaviru
infect
cytotox
therapi
use
cancer
chemotherapi
shown
specif
inhibitor
sar
coronaviru
vitro
studi
howev
vitro
vivo
studi
requir
confirm
especi
current
scientif
evid
interact
methotrex
total
studi
identifi
search
term
deem
suitabl
inclus
supplementari
tabl
search
identifi
strong
evid
use
ibuprofen
treatment
specif
one
studi
howev
link
sarscov
downregul
angiotensin
convert
upregul
ibuprofen
author
studi
investig
link
sever
symptom
patient
asthma
hypertens
studi
investig
nonsteroid
antiinflammatori
drug
one
look
indomethacin
studi
suggest
indomethacin
exhibit
potent
antivir
activ
canin
coronaviru
dramat
inhibit
viru
replic
protect
host
cell
virusinduc
damag
activ
also
observ
human
sarscov
concentr
dose
mgkg
gener
appear
posit
result
use
corticosteroid
viral
infect
sarscov
corticosteroid
wide
use
sarscov
outbreak
due
known
abil
modul
varieti
involv
cytokin
includ
variou
studi
human
note
corticosteroid
appear
effect
reduc
immunopatholog
damag
concern
centr
around
promot
viral
rebound
associ
advers
event
includ
acut
respiratori
distress
syndrom
one
laboratori
studi
treat
porcin
respiratori
coronaviru
infect
pig
dexamethason
suggest
one
two
dose
corticosteroid
acut
phase
infect
may
effect
allevi
earli
proinflammatori
respons
prolong
administr
may
play
role
enhanc
viral
replic
separ
chines
studi
separ
sarscov
patient
treatment
group
identifi
earli
highdos
steroid
combin
quinolon
produc
best
patient
outcom
nevertheless
one
review
state
current
recommend
corticosteroid
viral
diseas
dengu
glucocorticoidmedi
stimul
hypothalamicpituitaryadren
axi
also
drive
lymphocytopenia
may
promot
exagger
proinflammatori
respons
eventu
caus
worsen
pathogen
condit
current
literatur
give
conclus
evid
use
nsaid
treatment
patient
though
appear
evid
corticosteroid
may
benefici
treatment
sarscov
howev
import
note
specif
total
three
studi
identifi
two
deem
suitabl
inclus
supplementari
tabl
first
studi
research
letter
suggest
tnfa
implic
sever
immunebas
pulmonari
injuri
caus
sar
coronaviru
suggest
tnfa
inhibitor
could
potenti
treatment
acut
respiratori
diseas
syndrom
caus
coronaviru
second
studi
utilis
piglet
assess
efficaci
antitnfa
therapi
endotoxin
respiratori
diseas
observ
tnfa
blockad
associ
decreas
diseas
sever
current
evid
indic
tnfa
blockad
harm
patient
context
total
studi
identifi
second
search
strategi
suitabl
inclus
supplementari
tabl
first
search
strategi
found
hit
suggest
pathogenesi
sarscov
mediat
disproport
immun
respons
abil
viru
circumv
innat
immun
infect
also
observ
induc
proinflammatori
cytokin
gener
secret
cytokin
dysregul
local
inflammatori
respons
suggest
partial
respons
devast
acut
respiratori
distress
syndrom
moreov
observ
induc
high
level
least
week
diseas
onset
children
present
lower
level
cytokin
product
suggest
potenti
prognost
marker
diseas
sever
differ
molecul
relat
pathway
suggest
potenti
therapeut
target
sarscov
ssrna
mapk
current
scientif
evid
benefici
impact
inhibitor
modul
infect
understand
role
reduct
forthcom
pandem
progress
clinic
data
becom
avail
vitro
treatment
glycopyrronium
formoterol
budesonid
exert
addit
inhibitori
effect
viral
titer
cytokin
product
human
nasal
tracheal
epitheli
cell
fifteen
studi
yield
search
deem
suitabl
inclus
supplementari
tabl
baricitinib
olumi
jak
inhibitor
approv
european
medicin
agenc
februari
treatment
moderatetosever
activ
rheumatoid
arthriti
adult
inadequ
respons
one
diseasemodifi
antirheumat
drug
one
studi
suggest
use
baricitinib
reduc
viral
entri
inflamm
caus
virus
enter
cell
receptormedi
endocytosi
cellsurfac
protein
express
cell
kidney
blood
vessel
heart
alveola
type
cell
pulmonari
epithelia
may
receptor
use
infect
lung
cell
author
richardson
et
al
suggest
inhibit
adaptor
associ
protein
kinas
receptor
promot
endocytosi
involv
baricitinib
may
reduc
viral
entri
inflamm
patient
inositolrequir
transmembran
kinaseendoribonucleas
endoplasm
reticulum
stress
sensor
lead
increas
express
neg
regul
jakstat
suppressor
cytokin
signal
soc
therefor
may
novel
target
coronaviru
infect
requir
explor
tylophorinebas
compound
isol
plant
exert
potent
anticoronavir
activ
sarscov
merscov
nuclear
factor
kappalightchainenhanc
activ
b
cell
activ
common
proinflammatori
respons
host
cell
viral
infect
follow
vitro
analysi
yang
et
al
suggest
use
combin
therapi
sarscov
merscov
wherein
tylophorin
compound
known
target
transmiss
gastroenter
viru
inhibitor
synergis
block
altern
domin
activ
mediat
therefor
combin
treatment
inhibit
coronaviru
per
se
eg
viral
genom
replic
block
cellular
activ
coronavirus
promis
approach
develop
anticoronavir
current
studi
suggest
although
potenti
target
jakstat
pathway
manipul
treatment
coronavirus
earli
stage
requir
vitro
vivo
studi
confirm
therapeut
effect
total
studi
identifi
search
deem
suitabl
inclus
supplementari
tabl
mani
studi
vitro
studi
repeatedli
demonstr
increas
level
patient
infect
coronaviru
one
studi
investig
level
variou
inflammatori
cytokin
patient
china
compar
level
gener
sever
critic
ill
group
author
report
signific
differ
level
three
group
patient
anoth
studi
involv
consecut
sar
patient
admit
hong
kong
hospit
identifi
significantli
elev
level
within
first
day
follow
onset
infect
patient
sever
diseas
treat
puls
methylprednisolon
level
return
normal
day
seven
patient
less
sever
diseas
receiv
dosag
corticosteroid
cytokin
level
return
normal
rang
level
time
period
chines
studi
also
identifi
reduc
level
follow
administr
corticosteroid
suggest
inhibit
proinflammatori
cytokin
may
benefici
treatment
strategi
treatment
sar
third
studi
measur
serum
cytokin
level
four
patient
group
includ
control
patient
sar
patient
sever
sar
convalesc
sar
patient
suggest
longer
term
treatment
period
day
lowdos
steroid
alter
serum
cytokin
level
includ
one
rat
model
show
promis
result
receptor
antagonist
reduc
chemokin
express
infect
anim
howev
result
generalis
human
unfortun
one
studi
author
state
demonstr
first
time
inflamm
coronaviru
may
inhibit
antiinflammatori
cytokin
belong
famili
avail
abstract
therefor
evid
inform
back
claim
avail
overal
review
demonstr
although
evid
elev
patient
infect
coronaviru
present
evid
establish
role
blocker
treatment
human
literatur
howev
suggest
potenti
role
lowdos
corticosteroid
reduc
level
proinflammatori
marker
elev
part
immun
respons
may
role
sever
lung
damag
associ
human
coronavirus
almost
studi
investig
mpa
potenti
therapi
merscov
due
antivir
properti
six
select
studi
vitro
studi
two
vivo
one
clinic
exampl
four
review
therefor
overlap
result
supplementari
tabl
gener
vitro
studi
look
posit
mpa
target
papain
like
proteas
merscov
sarscov
studi
found
mpa
show
strong
inhibit
viru
low
mpa
use
combin
interferonbeta
ifnb
one
studi
appli
regim
marmoset
exhibit
sever
diseas
resembl
human
mer
report
high
viral
load
sever
even
fatal
diseas
author
studi
state
mpa
like
caus
harm
benefit
mer
patient
accord
review
mo
fisher
mpa
monotherapi
test
clinic
set
treatment
merscov
al
ghamdi
et
al
present
exampl
eight
patient
treat
mpa
merscov
seven
combin
eight
patient
surviv
howev
review
mo
fisher
state
group
patient
lower
acut
physiolog
chronic
health
evalu
ii
score
compar
other
cohort
receiv
varieti
antivir
agent
includ
ribavirin
ifna
steroid
antibiot
therefor
result
must
interpret
caution
whilst
vitro
studi
show
promis
result
mpa
mer
vivo
studi
suggest
use
like
caus
harm
benefit
henc
like
use
coronaviru
infect
clinic
studi
small
confirm
deni
benefici
use
merscov
patient
total
studi
identifi
search
term
three
deem
suitabl
inclus
supplementari
tabl
overal
literatur
appear
suggest
potenti
role
tacrolimu
treatment
human
coronavirus
case
studi
two
renal
transplant
recipi
test
posit
mer
cov
patient
treat
immunosuppress
regimen
tacrolimu
underw
full
recoveri
whilst
patient
treatment
regimen
succumb
infect
patient
eventu
made
full
recoveri
also
treat
antibacteri
therapi
reduc
dose
mycophenol
mofetil
therefor
possibl
conclud
patient
recoveri
due
tacrolimu
two
includ
studi
laboratori
studi
involv
cell
line
cultur
first
investig
pathway
coronaviru
viral
replic
potenti
antivir
therapeut
target
genomewid
sarscov
yeasttwohybrid
interact
screen
human
cdna
librari
identifi
protein
interact
partner
sarscov
nonstructur
protein
subsequ
author
investig
whether
tacrolimu
inhibit
viral
replic
human
coronavirus
verofm
cell
infect
sarscov
human
coronavirus
treat
result
show
effect
inhibit
viral
replic
sarscov
nontox
lowmicromolar
concentr
reduct
viral
titer
undetect
level
second
studi
confirm
inhibit
use
novel
nonimmunosuppress
deriv
context
lowmicromolar
noncytotox
concentr
cell
cultur
overal
small
amount
literatur
avail
suggest
potenti
role
tacrolimu
potent
antivir
treatment
human
coronavirus
import
note
howev
novel
diseas
may
differ
aetiolog
mechanist
action
compar
exist
strain
date
immunosuppress
drug
deriv
test
human
studi
warrant
clinic
set
laboratori
studi
identifi
inclus
studi
identifi
inclus
rapidli
progress
pandem
led
challeng
decisionmak
treatment
critic
unwel
patient
novel
viral
infect
parallel
doctor
across
multipl
specialti
make
clinic
decis
appropri
continu
treatment
patient
chronic
ill
requir
immunesuppress
medic
systemat
review
look
provid
guidanc
current
avail
literatur
pandem
progress
collect
effort
captur
data
prospect
trial
requir
sponsor
random
control
trial
recruit
patient
random
receiv
immun
modulatori
drug
may
affect
collect
data
diseas
outcom
consid
interim
analysi
potenti
advantag
disadvantag
associ
use
one
medic
lowdos
prednisolon
tacrolimu
therapi
may
benefici
impact
cours
observ
requir
valid
mycophenol
mofetil
pictur
less
clear
conflict
data
preclin
studi
definit
evid
specif
cytotox
drug
lowdos
methotrex
autoimmun
diseas
nsaid
jak
kinas
inhibitor
antitnfa
biolog
agent
contraind
evid
peak
level
associ
sever
pulmonari
complic
ongo
studi
blockad
pathway
ration
hope
inform
practic
pandem
progress
would
like
thank
variou
funder
guy
st
thoma
chariti
cancer
research
uk
cruk
king
health
partner
centr
author
conflict
interest
declar
